The study drew on 321 men from the MACS/WIHS Combined Cohort Study, one of the longest-running observational research programs on HIV in the United States. Roughly 65 percent of the participants were living with HIV, and the group’s median age was 62 years. Using high-resolution B-mode ultrasound, the investigators examined each participant’s carotid arteries, the large vessels that carry blood to the brain, and looked for plaque buildup with an arterial wall thickness exceeding 1.5 millimeters, the standard marker of subclinical atherosclerosis, meaning artery disease that has not yet caused symptoms. Just under a third of the men, 31.5 percent, had detectable carotid plaque.

What makes the study methodologically striking is its layered design. The researchers first measured 14 serum sex hormones along with sex hormone-binding globulin, or SHBG, the glycoprotein that binds sex steroids in the bloodstream and regulates how much free, biologically active hormone circulates in the body. Then, in a subset of 312 men, they profiled 986 plasma metabolites using liquid chromatography-tandem mass spectrometry, a technique that separates and identifies small molecules with high precision, and quantified 2,883 plasma proteins on the Olink Explore 3072 platform, an affinity-based proteomics assay that measures proteins across inflammatory, metabolic, and cardiovascular pathways. Stool samples underwent metagenomic sequencing, allowing the team to identify gut microbial species and their relative abundances.

The central question was whether sex hormones relate to artery plaque differently in men with HIV compared with men without it, and whether the molecular fingerprints of those hormones might explain the connection. The team built what they call omics scores: linear combinations of the gut microbial species, metabolites, and proteins most strongly associated with a given hormone. If a hormone’s downstream molecular signature is also linked to plaque, that signature offers clues about mechanism, not just correlation.

The headline result concerned SHBG. In men with HIV, each one-standard-deviation increase in SHBG was associated with 40 percent lower odds of carotid plaque, with an odds ratio of 0.60 and a 95 percent confidence interval of 0.41 to 0.90. No such protective association appeared in the men without HIV, and the pattern of associations for the other sex hormones diverged between the two groups as well, hinting that HIV itself, or its long-term interplay with antiretroviral therapy and chronic immune activation, alters how the endocrine system relates to vascular health.

The multi-omics layer then revealed what SHBG is traveling with. Higher SHBG levels tracked with a measurably different overall gut microbial composition, including lower abundance of species from the genera Prevotella, Fibrobacter, and Coprococcus. They also tracked with higher levels of certain circulating metabolites, predominantly lipids and carnitine-related compounds, molecules that sit at the intersection of fat transport and mitochondrial energy metabolism, and with a protein profile enriched in the cell-cell adhesion pathway, the molecular machinery that governs how immune cells stick to blood vessel walls, a key early step in plaque formation.

Crucially, several of the individual molecules associated with SHBG were themselves associated with plaque in men with HIV. The microbial species Mediterranea massiliensis, phosphatidylcholine-based lipids, and proteins involved in immune response pathways all appeared in both lists, connecting SHBG to artery disease through three independent biological domains. When the researchers consolidated this signal into the three omics scores, the results converged: all three scores were inter-correlated with one another and each was inversely associated with carotid plaque in men with HIV. A species score, a metabolite score, and a protein score, built from completely different measurement technologies, all pointing the same direction.

The contrast group told a different story. Among men without HIV, the only significant hormone-plaque link was estrone-sulfate, a sulfated form of estrogen, which was positively associated with plaque, with an odds ratio of 3.80 and a 95 percent confidence interval of 1.41 to 10.22. Notably, estrone-sulfate showed no associations with any gut microbial species, metabolites, or proteins, suggesting its relationship to artery disease may run through a different mechanism, or that the study lacked the statistical power to detect one. This asymmetry between the two groups is one of the paper’s most provocative implications: the cardiovascular meaning of a given hormone appears to depend on HIV status.

The findings carry real-world weight because people living with HIV face an elevated burden of cardiovascular disease that traditional risk calculators do not fully capture. Even with viral suppression maintained by antiretroviral therapy, chronic inflammation, immune dysregulation, and metabolic changes persist, and heart attacks and strokes occur more often than expected. If SHBG, a molecule that can be measured cheaply in serum, genuinely marks, or perhaps mediates, a protective vascular state in this population, it could become part of risk stratification and eventually a therapeutic target.

The word “perhaps” matters here. This is a cross-sectional observational study: hormones and omics profiles and plaque were measured at the same time, so the data cannot prove that high SHBG causes less plaque. Reverse causation is plausible, since systemic illness, inflammation, and metabolic dysfunction are known to lower SHBG levels, meaning that plaque itself could conceivably drag the protein down. The authors’ exploratory mediation analyses, testing whether the omics scores statistically explain the SHBG-plaque association, are suggestive rather than definitive. Longitudinal follow-up, and ideally interventions that raise SHBG, would be needed to establish causality.

Still, the study exemplifies where cardiovascular research is heading. Rather than testing a single biomarker against a single outcome, the multi-omics approach maps the shadow a molecule casts across the gut microbiome, the metabolome, and the proteome, then checks whether those shadows fall on disease itself. SHBG, often treated as a passive transport protein, emerges from this analysis as a hub connected to gut ecology, lipid metabolism, carnitine handling, and vascular immune biology. Whether the protective signal holds over time, and whether it extends to women with HIV and other populations, will be the natural next questions. For now, the study offers men living with HIV a new molecular clue to a persistent clinical puzzle: why their arteries age faster than their calendar risk factors predict.

This research, led by Prof. Yang Li and colleagues at the Centre for Individualised Infection Medicine (CiiM), a joint initiative of the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School, represents the first large-scale study using integrative multi-omics data to explore the molecular drivers of HIV-related comorbidities. Utilizing data from the 2000HIV Study cohort based in the Netherlands, the team analyzed biological samples from over 1,300 individuals living with HIV. This cohort’s extensive dataset includes genomic, proteomic, and metabolomic profiles, offering unprecedented resolution into the molecular complexities underlying disease processes in these patients.

At the heart of this study is the concept of chronic inflammation—a persistent, low-grade inflammatory state that many people with HIV experience despite effective viral suppression. Chronic inflammation not only accelerates cellular aging but also predisposes individuals to conditions such as atherosclerosis, fibrosis, and malignancies. By correlating multi-omics layers of data, the researchers sought to identify specific molecular players and pathways that are implicated in driving these inflammatory and disease states.

One of the key innovations of this study was the integration of immune response profiling alongside traditional molecular analyses. The strength and regulation of the immune response is a dynamic measure of immune system fitness and resilience to pathogens. “By incorporating parameters that quantify immune responsiveness, we were able to connect molecular abnormalities directly to functional immune outcomes,” explains co-first author Nienke van Unen. This enabled the identification of not only disease markers but potential predictors of how an individual’s immune system might react to infections or additional physiological challenges.

The team’s analytical approach revealed a spectrum of previously undetected molecular correlations with major comorbidities, such as cardiovascular disease, carotid artery plaque formation, and chronic obstructive pulmonary disease (COPD). These findings illuminate a complex network of gene expression changes, protein signaling aberrations, and metabolic disruptions that collectively promote disease progression. “Our data uncovered molecular patterns that had evaded prior detection due to the isolated study of single omics layers,” states lead author Javier Botey-Bataller. The depth of these insights is powered by cross-level molecular comparison, which provides a systemic picture of pathogenesis rather than fragmented snapshots.

Crucially, the researchers identified molecular indicators capable of predicting the intensity of immune activation. Excessive immune responses, in particular, have been implicated as the principal drivers of systemic inflammation linked to comorbidities in HIV-positive individuals. The elucidation of these predictive markers opens the possibility for tailored therapeutic interventions aimed at modulating immune hyperactivation before irreversible tissue damage occurs. Such stratified approaches could profoundly improve long-term outcomes by mitigating the chronic inflammatory milieu.

Among the novel discoveries was a specific genetic variant of the NLRP12 gene, which emerged as a potential key regulator of inflammatory processes. NLRP12 belongs to a family of genes known to modulate inflammasome activity—a critical component of innate immunity and inflammation control. Participants harboring this variant exhibited markedly elevated inflammation levels regardless of HIV status, suggesting a broader susceptibility to inflammatory diseases beyond HIV infection itself. This insight underscores the interplay between host genetics and inflammation, offering new avenues for risk stratification and precision medicine.

The multi-omics dataset assembled for this investigation is openly accessible to the scientific community, fostering collaborative research and enabling further exploration into the molecular etiology of HIV-associated comorbidities. The availability of this rich resource is a significant contribution, providing a foundational platform from which future studies can unravel additional mechanistic details or validate therapeutic targets.

Importantly, this study sets a precedent for utilizing integrative molecular profiling in infectious disease research. By coupling genomic, proteomic, metabolomic, and immunological data, researchers can transcend traditional siloed analyses and capture the multifactorial nature of disease processes. This holistic methodology aligns with the emerging paradigm of individualized medicine, wherein patient management and treatment strategies are informed by nuanced molecular signatures tailored to each individual’s biology.

The implications of these findings extend beyond HIV research, as chronic inflammation is a common denominator in many age-related diseases and infections. Understanding how genetic variants like NLRP12 influence inflammatory pathways may have relevance for broader populations suffering from inflammatory and autoimmune disorders. Furthermore, the principle of mapping molecular landscapes to decode disease networks is applicable to numerous complex diseases, from cancer to neurodegeneration.

From a clinical perspective, the insights gathered could translate into more effective monitoring strategies for people living with HIV. The identification of molecular markers associated with comorbid conditions raises the possibility of developing blood-based diagnostic tests or biomarker panels that predict disease risk or progression. Early detection and intervention remain critical in managing these patients’ health, particularly given the accelerated aging and increased comorbidity burden observed.

Looking ahead, the research team envisions leveraging this molecular map to guide experimental studies aimed at dissecting the functional roles of specific genes and proteins in driving comorbidities. Such mechanistic work will be vital for validating candidate therapeutic targets and designing novel interventions. With the global population of people living with HIV continuing to grow, particularly among aging cohorts, these advances hold promise for improving quality of life and reducing healthcare burdens.

In sum, the study published in Nature Medicine marks a pivotal advancement in understanding the biological intricacies underpinning HIV-related comorbidities. By harnessing the power of multi-omics data and integrating immune response metrics, the research opens new horizons for precision medicine approaches tailored to the unique molecular profiles of individuals living with HIV. This work exemplifies the transformative potential of big data in biomedical research, forging a path toward more personalized, effective interventions for chronic inflammatory diseases.

—

Subject of Research: Genetic and molecular mechanisms underlying comorbidities in people living with HIV

Article Title: Genetic and molecular landscape of comorbidities in people living with HIV

News Publication Date: 20-Aug-2025

Web References: http://dx.doi.org/10.1038/s41591-025-03887-1

Keywords: HIV, comorbidities, chronic inflammation, multi-omics, personalized medicine, immune response, NLRP12 gene, cardiovascular disease, COPD, proteomics, metabolomics, genomics